Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Author:
Rafael Bejar
Search for other papers by Rafael Bejar in
Current site
Google Scholar
PubMed Close
 MD, PhD
Volume/Issue:
Volume 17: Issue 11.5
Online Publication Date:
Nov 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5032
Restricted access

Often unrecognized and underdiagnosed, myelodysplastic syndromes (MDS) are a rare group of cancers in which the bone marrow fails to produce sufficient healthy blood cells. Although patients with lower-risk MDS can live for >5 years, those with high-risk disease that evolves into acute myeloid leukemia is associated with significantly lower overall survival. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Rafael Bejar summarized current standard treatment options for patients with MDS and discussed the importance of genetic testing to identify mutations that may impact treatment. Finally, Dr. Bejar described emerging personalized treatment strategies for the management of this disease.

Disclosures: Dr. Bejar has disclosed that he is a scientific advisor for Celgene, NeoGenomics, AbbVie, Astex, and Daiichi-Sankyo; has received grant/research support from Takeda and Celgene; and is on the advisory board for Celgene/Acceleron.

Correspondence: Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC 0820, La Jolla, CA 92093. Email: rabejar@ucsd.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820–829.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017;18:1338–1347.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood 2014;124:2793–2803.

  • 4.

    Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee [abstract]. Blood 2015;126:Abstract 637.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 2017;376:536–547.

  • 6.

    Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 2016;375:2023–2036.

  • 7.

    Bykov VJ, Zhang Q, Zhang M, et al. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol 2016;6:21.

Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
4
Article Category:
Research Article
Print Publication Date:
01 Nov 2019
Online Publication Date:
Nov 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3689 1466 420
PDF Downloads 1364 84 3
EPUB Downloads 0 0 0